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DOI 10.1016/j.ccr.2010.10.020SUMMARYMutational activation of KRas is the first and most frequently detected genetic lesion in pancreatic ductal
adenocarcinoma (PDAC). However, the precise role of oncogenic KRas in the pathogenesis of PDAC is not
fully understood. Here, we report that the endogenous expression of oncogenic KRas suppresses premature
senescence in primary pancreatic duct epithelial cells (PDEC). Oncogenic KRas-mediated senescence
bypass is conferred by the upregulation of the basic helix-loop-helix transcription factor Twist that in turn
abrogates p16INK4A induction. Moreover, the KRas-Twist-p16INK4A senescence bypass pathway is employed
in vivo to prevent inflammation-associated senescence of pancreatic ductal epithelium. Our findings indicate
that oncogenic KRas could contribute to PDAC initiation by protecting cells from entering a state of perma-
nent growth arrest.INTRODUCTION
Ras proteins comprise a family of signal-transducing GTPases
that are frequently mutated in human cancers. Oncogenic Ras
mutations lock the protein in its GTP-bound form thus permitting
its constitutive interaction with and activation of multiple effec-
tors (Downward, 2003). The pathogenic role of oncogenic Ras
has been attributed primarily to its promoting effects on cell
proliferation and cell survival. In contrast, in normal primary cells
oncogenic Ras can cause a permanent proliferative arrest
known as premature senescence (Serrano et al., 1997). The
induction of senescence by oncogenic Ras is largely mediated
by the upregulation of inhibitors of cell proliferation including
p16INK4A, p19ARF, p21CIP, and p53 and is thought to serve as
a tumor suppressive process by preventing the expansion of
cells bearing mutant Ras (Lowe et al., 2004). However, the
capacity of oncogenic Ras to provoke senescence varies
considerably depending on cellular context and biological
setting. For example, the ectopic expression of oncogenic Ras
in fibroblasts at supraphysiological levels can trigger senes-
cence, whereas expression of oncogenic Ras at physiologicalSignificance
Cellular senescence, a state of stable proliferative arrest, is a p
represents an important step in tumor development. In this st
a p16INK4A-dependent senescence of pancreatic ductal cells
through the upregulation of Twist and the consequent suppres
anism by which oncogenic KRas may contribute to pancrea
KRas-mediated senescence escape as a potential target for th
448 Cancer Cell 18, 448–458, November 16, 2010 ª2010 Elsevier Inclevels fails to engage the senescence machinery (Serrano
et al., 1997; Tuveson et al., 2004). In addition, although some
studies using mouse models of oncogenic KRas-driven tumori-
genesis have documented the presence of senescent preneo-
plastic lesions in lung, colon, and pancreatic tissues (Bennecke
et al., 2010; Collado et al., 2005; Morton et al., 2010), others
have reported that senescence could not be detected in onco-
genic KRas-expressing tissues (Tuveson et al., 2004). Thus, it
remains unclear to what extent the implementation of the senes-
cence program is linked to the oncogenic potential of mutated
Ras.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer-related death in the United States and
carries a median survival of <6 months (Jemal et al., 2009;
Warshaw and Fernandez-del Castillo, 1992). A distinguishing
molecular feature of PDAC is the presence of activating KRas
mutations in >90% of tumors (Almoguera et al., 1988). Because
of their unusually high prevalence and their detection at very
early stages of disease, KRas mutations are considered a key
genetic determinant in the initiation of PDAC. In support of
this postulate, mice engineered to express mutated KRasotent tumor suppressor mechanism and senescence bypass
udy, we demonstrate that inflammatory stress can provoke
, and that this response is abrogated by oncogenic KRas
sion of p16INK4A expression. These findings identify a mech-
tic tumorigenesis and warrant the evaluation of oncogenic
erapeutic intervention.
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Figure 1. Oncogenic KRas Protects PDEC from Undergoing Premature Senescence
(A) PCR analysis of genomic DNA prepared from LSL-KrasG12D PDEC infected with adenoviral-GFP (WT) or adenoviral-Cre (KrasG12D). The excision-recombina-
tion event of the LSL cassette leaves behind a single LoxP (1 lox) site.
(B) Measurement of Ras activation in WT and KrasG12D PDEC by GST-RBD pull-down assay. a-Tubulin serves as a loading control. IB: immunoblot; WCL: whole
cell lysates.
(C) Growth analysis of WT and KrasG12D PDEC. The number of DAPI-stained nuclei was counted in nine random fields of view (FOV) each containing at least 50
cells at day 2, 5, 8, and 14. The average number of nuclei present in the FOV at each time point was then normalized to the average number of nuclei per FOV at
day 2. Error bars indicate standard deviation (SD). Data are representative of five independent experiments.
(D) SA-b-gal staining of WT and KrasG12D PDEC cultures at day 8. Scale bar represents 100 mm.
(E) Quantification of SA-b-gal staining inWT and KrasG12D PDEC cultures at day 2, 5, 8, 11, and 14. Cells were counterstained with Hoechst 33342 for b-gal quan-
tification. Error bars indicate SD (n = 6 FOV). Data are representative of five independent experiments. See also Figure S1.
Cancer Cell
Suppression of Senescence by Oncogenic KRasspecifically in the pancreas sustain a spectrum of neoplastic
lesions that mirror histologically those observed in humans
(Hingorani et al., 2003). Thus, understanding the mechanisms
by which KRas mutations contribute to PDAC development is
critical for the identification of effective strategies to detect and
treat PDAC. To clarify the relationship between the mutational
activation of KRas, induction of senescence and pancreatic
tumorigenesis, we have examined the consequences of endog-
enous oncogenic KRas expression in primary pancreatic duct
epithelial cells (PDEC), a potential cell of origin for PDAC.
RESULTS
To assess the role of oncogenic KRas in pancreatic tumorigen-
esis, we have used a previously described cell culture system
for primary mouse PDEC (Agbunag and Bar-Sagi, 2004; Agbu-
nag et al., 2006). The endogenous expression of oncogenic
KRas in these cells was achieved by their isolation from condi-Cantional oncogenic KRas (LSL-KrasG12D) knock-in mice (Jackson
et al., 2001) followed by infection with recombinant adenoviruses
encoding Cre recombinase. As a control, PDEC derived from the
samemicewere infectedwith recombinant adenoviruses encod-
ing green fluorescent protein (GFP). The excision of the LSL
cassette was verified by PCR (Figure 1A) and the expression of
the KrasG12D allele was indicated by the pronounced increase
in the levels of KRas-GTP (Figure 1B).
We have previously shown that primary PDECundergo prema-
ture senescence in culture (Agbunag and Bar-Sagi, 2004).
Consistent with these observations, control PDEC, hereafter
referred to as wild-type (WT), ceased growing within 5 days after
plating, adopted an enlarged flattened morphology, and dis-
played senescence-associated-b-galactosidase (SA-b-gal)
activity starting at day 8 and peaking at days 12–15 (Figures
1C–1E; see Figure S1 available online). In contrast, the vast
majority of KRasG12D-expressing PDEC, hereafter referred to as
KrasG12D, continued proliferating and showed no SA-b-galcer Cell 18, 448–458, November 16, 2010 ª2010 Elsevier Inc. 449
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Figure 2. Oncogenic KRas Confers Bypass of Premature Senescence in PDEC through the Suppression of p16INK4A Induction
(A) Western blot analysis for senescence effectors in WT and KrasG12D PDEC cultures at day 0 and day 8. Equal loading was verified with anti-a-tubulin.
(B) Quantitative RT-PCR analysis of p16INK4A in WT and KrasG12D PDEC cultures at day 0 and day 8. Error bars indicate SD (n = 3).
(C) Quantification of SA-b-gal staining in p16Ink4a+/, p16Ink4a/, p53+/, p53/ PDEC cultures at day 8. Error bars indicate SD (n = 6 FOV). Data are represen-
tative of three independent experiments.
Cancer Cell
Suppression of Senescence by Oncogenic KRasactivity (Figures 1C–1E; Figure S1). These findings indicate that
oncogenic KRas can protect PDEC from premature senescence.
To investigate the mechanisms by which oncogenic KRas
represses PDEC senescence, we first assessed the expression
levels of the major senescence effectors p16INK4A, p19ARF,
p21CIP, and p53 in WT and KrasG12D PDEC by western blot anal-
ysis. As shown in Figure 2A, in WT PDEC the levels of p19ARF,
p21CIP, and p53 remained essentially unchanged as the cells
matured in culture. In contrast, p16INK4A protein and message
levels increased markedly (Figures 2A and 2B) suggesting that
the induction of premature senescence in PDEC might depend
preferentially on p16INK4A upregulation. To test this idea directly,
we examined the senescence phenotype of PDEC isolated from
p16Ink4a / mice and p53/ mice (Jacks et al., 1994; Serrano
et al., 1996) by SA-b-gal staining. Loss of p53 had no effect on
the extent of PDEC senescence, whereas p16INK4A deficiency
led to a significant reduction in PDEC senescence (Figure 2C).
The senescence phenotype of the PDEC used as controls for
these experiments (p16Ink4a+/ and p53+/) was indistinguish-
able from that observed in WT PDEC (data not shown). These
observations suggest that premature senescence of PDEC
requires the induction of p16INK4A but not p53. Noticeably, the
induction of p16INK4A expression was abrogated in KrasG12D
PDEC (Figures 2A and 2B) indicating that oncogenic KRas might
confer senescence bypass via the suppression of p16INK4A
induction.
Next we sought to determine the mechanism by which onco-
genic KRas prevents the upregulation of p16INK4A. We focused
our attention on the basic helix-loop-helix transcription factor
Twist (also known as Twist1) because of its documented ability
to override premature senescence by abrogating p16INK4A
expression (Ansieau et al., 2008) and its recently reported
genetic interactions with Ras (Hurlbut et al., 2009). To examine
the effect of oncogenic KRas on Twist expression, the levels of
Twist mRNA and protein in WT and KrasG12D PDEC were
compared. As illustrated in Figures 3A and 3B, Twist levels450 Cancer Cell 18, 448–458, November 16, 2010 ª2010 Elsevier Incwere markedly increased in KrasG12D PDEC indicating that Twist
transcription might be regulated by oncogenic KRas signaling.
Of note, oncogenic KRas did not induce the expression of the
Twist1 homolog, Twist2 (formerly known as Dermo-1) (Li et al.,
1995) (data not shown). Initial analysis of Ras effector pathways
that might target Twist transcription failed to implicate the Ras-
ERK and Ras-PI3K signaling axes (data not shown). To establish
whether Twist is essential for oncogenic KRas-mediated senes-
cence bypass in PDEC, Twist expression was suppressed in
KrasG12D PDEC using RNA interference. A significant attenuation
of Twist mRNA and protein expression was attained using two
independent targeting sequences (Figures 3C and 3D). The
reduction in Twist expression coincided with a specific increase
in p16INK4A expression (Figures 3D and 3E) and was accompa-
nied by the induction of SA-b-gal activity (Figures 3F and 3G).
In contrast, the knockdown of Twist in p16Ink4a/ PDEC was
without an effect on SA-b-gal activity (Figure S2A). Together,
these results indicate that Twist is a critical mediator of onco-
genic KRas-dependent suppression of p16INK4A expression
and senescence bypass in PDEC. Although Twist has been
shown to cooperate with Ras in the induction of the epithelial-
mesenchymal transition (EMT) (Ansieau et al., 2008), the expres-
sion of Twist in KrasG12D PDEC was not accompanied by the
activation of the EMT program, as reflected by the persistence
of expression of the epithelial marker E-cadherin, and absence
of induction of the mesenchymal markers vimentin and
a-smooth muscle actin (a-SMA) (Figures S2B–S2D).
To investigate thephysiological relevanceof senescenceabro-
gationbyoncogenicKRas,weset out to identify an in vivocontext
in which premature senescence occurs in a p16INK4A-dependent
manner. Because inflammation is a well-established risk factor
for pancreatic cancer (Lowenfels et al., 1993; Malka et al.,
2002) and pro-inflammatory signals have been implicated in
senescence induction (Acosta et al., 2008; Kuilman et al.,
2008), we examined whether inflammatory conditions may
trigger senescence in pancreatic ductal epithelium in vivo. To.
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Figure 3. Oncogenic KRas-Mediated Bypass of Premature Senescence in PDEC Is Dependent on Twist
(A) Western blot analysis for Twist in WT and KrasG12D PDEC cultures at day 8. a-Tubulin serves as a loading control.
(B) Quantitative RT-PCR analysis of Twist in WT and KrasG12D PDEC cultures at day 0 and day 8. Error bars indicate SD (n = 3).
(C) Quantitative RT-PCR analysis of Twist in KrasG12D PDEC cultures 8 days after infection with recombinant lentiviruses encoding shRNA targeted against Gfp
(control shRNA) or Twist (Twist shRNA3 or Twist shRNA5). Error bars indicate SD (n = 3).
(D) Western blot analysis for Twist and senescence effectors in KrasG12D PDEC cultures 8 days after infection with recombinant lentiviruses encoding control
shRNA, Twist shRNA3, or Twist shRNA5. Equal loading was verified with anti-a-tubulin.
(E) Quantitative RT-PCR analysis of p16INK4A in KrasG12D PDEC cultures 8 days after infection with recombinant lentiviruses encoding control shRNA, Twist
shRNA3, or Twist shRNA5. Error bars indicate SD (n = 3). *p value < 0.05.
(F) SA-b-gal staining of KrasG12DPDEC cultures 8 days after infection with recombinant lentiviruses encoding control shRNA or Twist shRNA3. Scale bar, 100 mm.
(G) Quantification of SA-b-gal staining in KrasG12D PDEC cultures 8 days after infection with recombinant lentiviruses encoding control shRNA, Twist shRNA3, or
Twist shRNA5. Error bars indicate SD (n = 6 FOV). *p value < 0.05. Data are representative of three independent experiments. See also Figure S2.
Cancer Cell
Suppression of Senescence by Oncogenic KRaselicit pancreatic inflammation, mice were subjected to a series of
eight hourly intraperitoneal injections of supraphysiological levels
of cerulein over 2 consecutive days. This protocol has been
shown to induce exocrine pancreatic injury followed by a mild
inflammatory response (Carriere et al., 2009; Jensen et al.,
2005; Willemer et al., 1992). Three days after the last ceruleinCaninjection, pancreata were harvested and subjected to SA-b-gal
assays. As illustrated in Figure 4A, mock-injected pancreata
had no detectable SA-b-gal activity, whereas pancreatic ducts
in cerulein-treated pancreata displayed pronounced SA-b-gal
activity. Consistent with the growth arrest state attributed to sen-
escent cells, the SA-b-gal-positive ductal cells were negative forcer Cell 18, 448–458, November 16, 2010 ª2010 Elsevier Inc. 451
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Figure 4. Inflammatory Insult Triggers Premature Senescence in Pancreatic Ductal Epithelium In Vivo
(A–D) Cerulein was administered to 1-month-old mice as 8 hourly intraperitoneal injections (50 ng/g of body weight/injection) for 2 days. Three days after the last
cerulein injection, pancreata were harvested. At least three sections were analyzed per animal (n = 5 per genotype per treatment). (A) SA-b-gal staining and immu-
nofluorescence staining for p16INK4A and CK19 on consecutive sections of pancreata fromWTmice treatedwith cerulein or saline (mock). CK19was used to iden-
tify ductal cells. Nuclei were counterstained with DAPI. Arrowheadsmark corresponding areas. (B andC) SA-b-gal staining, hematoxylin and eosin (H&E) staining,
and immunofluorescence staining for CD45 on consecutive sections of pancreata from WT mice treated with cerulein. Pancreatic ducts in unaffected (B) or in-
flamed (C) areas are from the same tissue section. CD45 was used to identify leukocytes. Nuclei were counterstained with DAPI. ac: acinus; du: duct; is: islet;
asterisk: immune infiltrate. (D) Quantification of SA-b-gal staining in pancreata from WT mice treated with cerulein or saline (mock). Pancreatic ducts
bearingR10% b-gal-positive cells in each duct were scored as positive. At least four pancreatic ducts were scored in eachmouse. Error bars indicate SD (n = 5).
(E and F) Immunohistochemical analysis of p16INK4A in human chronic pancreatitis tissue samples. Representative areas of normal pancreatic (E) and pancreatitis
(F) tissues are shown. Scale bars represent 50 mm (A–C) and 100 mm (E and F). See also Figure S3.
Cancer Cell
Suppression of Senescence by Oncogenic KRasthe proliferation marker Ki67 (Figure S3). It should be noted that
the inflammatory response after cerulein-induced injury is focal.
Significantly, only pancreatic ducts that were adjacent to in-
flamed areas as evident by loss of acinar cells and presence of
immune infiltrates stained positively for SA-b-gal activity (Figures
4B–4D). This spatial correlation indicates that the pancreatic
ductal epithelium can be induced to undergo premature senes-
cence in vivo in response to inflammatory insults.452 Cancer Cell 18, 448–458, November 16, 2010 ª2010 Elsevier IncTo explore the relationship between inflammation-induced
premature senescence in pancreatic ducts and p16INK4A expres-
sion, the levels of p16INK4A were assessed in pancreata from
mock-injected and cerulein-injected mice by immunofluores-
cence staining. In agreement with published data documenting
the lack of p16INK4A expression in the mouse pancreas (Krishna-
murthy et al., 2004), pancreatic ducts from mock-injected mice
were negative for p16INK4A staining (Figure 4A). In contrast,.
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Figure 5. Inflammation-Induced Premature Senescence in Pancreatic Ductal Epithelium Depends on p16INK4A Upregulation
Cerulein was administered as described in Figure 4. At least three sections were analyzed per animal (n = 5 per genotype per treatment).
(A and B) SA-b-gal staining and H&E staining on consecutive sections of pancreata from p16Ink4a/ (A) and p53/mice (B) treated with cerulein or saline (mock).
Ac: acinus; du: duct; is: islet; asterisk: immune infiltrate. Scale bars, 50 mm.
(C) Quantification of SA-b-gal staining in pancreata from WT, p16Ink4a/, and p53/ mice treated with cerulein. Only pancreatic ducts in inflamed areas were
counted. At least four pancreatic ducts were scored in each mouse. Error bars indicate SD (n = 5). See also Figure S4.
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Suppression of Senescence by Oncogenic KRasp16INK4A staining was robust in pancreatic ducts from cerulein-
injected animals (Figure 4A). Significantly, human chronic
pancreatitis was found to be also associated with the ductal up-
regulation of p16INK4A (Figures 4E and 4F). These results along
with the observation that strong p16INK4A immunostaining coin-
cided with high SA-b-gal activity (Figure 4A) raised the possibility
that inflammation-induced premature senescence in pancreatic
ducts is conferred by the upregulation of p16INK4A. To test this
idea, we treated p16Ink4a/ mice with cerulein and analyzed
the pancreata for SA-b-gal activity. As shown in Figures 5A
and 5C, inflammation-induced premature senescence of the
ductal epithelium was rescued by p16INK4A-deficiency. By
comparison, pancreatic ducts from cerulein-injected p53/
mice retained the capacity to undergo premature senescence
(Figures 5B and 5C). The inflammatory response per se did not
appear to be altered by p16INK4A deficiency as determined by
gross inspection of tissue sections and the abundance of
CD45-positive cells (Figure S4). These observations indicate
that p16INK4A is required for inflammation-associated premature
senescence in pancreatic ducts and p53 is dispensable for this
process.
Given our in vitro findings that oncogenic KRas inhibits prema-
ture senescence in PDEC via the suppression of p16INK4A, we
next asked whether oncogenic KRas can circumvent inflamma-
tion-induced premature senescence in pancreatic ductal epithe-
lium in vivo. The LSL-KrasG12D allele was conditionally activated
in the pancreas by interbreeding LSL-KrasG12D mice withCanp48-Cre mice (Kawaguchi et al., 2002). Lineage tracing studies
previously demonstrated uniform expression of Cre recombi-
nase throughout the pancreas in p48-Cre mice (Kawaguchi
et al., 2002) and PCR analysis confirmed the presence of the re-
combined allele in pancreatic ducts of p48-Cre;LSL-KrasG12D
mice used for the experiments (Figure S5A). As illustrated in
Figures 6A–6C, pancreatic ducts in p48-Cre;LSL-KrasG12D
mice treated with cerulein failed to senesce, and the abrogation
of senescence was associated with suppression of p16INK4A
expression. These results indicate that endogenous expression
of oncogenic KRas in vivo protects the pancreatic ductal epithe-
lium from undergoing premature senescence by suppressing the
induction of p16INK4A in response to inflammation. Significantly,
Twist levels were increased in pancreata from p48-Cre;LSL-
KrasG12D mice (Figure 6D) implicating Twist in the protective
effects of oncogenic KRas on inflammation-associated senes-
cence. Consistent with our in vitro findings, the expression of
Twist in pancreata from p48-Cre;LSL-KrasG12D mice was not
associated with EMT induction as demonstrated by persistent
expression of E-cadherin and absence of a-SMA induction in
pancreatic ducts (Figures S5B and S5C).
DISCUSSION
In the present study, we describe a previously unrecognized
functional facet of oncogenic KRas—the capacity to suppress
premature senescence of pancreatic ductal epithelium.cer Cell 18, 448–458, November 16, 2010 ª2010 Elsevier Inc. 453
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Figure 6. Inflammation-Associated Premature Senescence of Pancreatic Ductal Epithelium In Vivo Can be Blocked by Oncogenic KRas
through the Suppression of p16INK4A
Cerulein was administered as described in Figure 4. At least three sections were analyzed per animal (n = 5 per genotype per treatment).
(A andB) SA-b-gal staining and immunofluorescence staining for p16INK4A andCK19on consecutive sections of pancreata fromWT (A) andp48-Cre;LSL-KrasG12D
(B) mice treated with cerulein or saline (mock). CK19 was used to identify ductal cells. Nuclei were counterstained with DAPI. Arrowheads mark corresponding
areas. Scale bars, 50 mm.
(C) Quantification of SA-b-gal staining in pancreata fromWT and p48-Cre;LSL-KrasG12Dmice treated with cerulein. Only pancreatic ducts in inflamed areas were
counted. At least four pancreatic ducts were scored in each mouse. Error bars indicate SD (n = 5).
(D)QuantitativeRT-PCRanalysis of Twist in pancreata fromWTandp48-Cre;LSL-KrasG12Dmice treatedwith cerulein or saline (mock). Error bars indicate SD (n =5
per genotype). *p value < 0.05. See also Figure S5.
Cancer Cell
Suppression of Senescence by Oncogenic KRasBecause in the setting of evolving pancreatic neoplasms, acti-
vating KRas mutations are the first genetic alteration to be de-
tected (Hruban et al., 2000), senescence bypass could serve
as a mechanism to impart selective advantage to the cellular
precursors of pancreatic cancer. Moreover, the enhanced
fitness that oncogenic KRas confers on pancreatic ductal
epithelium may explain why KRas mutations can be tolerated
by these cells.454 Cancer Cell 18, 448–458, November 16, 2010 ª2010 Elsevier IncThe propensity of cultured primary cells to undergo premature
senescence has been described before and has been attributed
to the induction of p16INK4A expression in response to stress
conditions imposed by an inappropriate growth environment
(Ben-Porath and Weinberg, 2004; Sherr and DePinho, 2000).
The senescence displayed by cultured PDEC likely reflects
a similar mechanism as indicated by the increase in p16INK4A
levels observed when the cells are maintained in culture. In vivo.
Cancer Cell
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cence induction has not been firmly established. Although
p16INK4A levels are elevated in aging or stressed senescent
tissues in vivo, so arep53 levels, and studies usinggenetically en-
gineeredmice have implicated both p16INK4A andp53 in affecting
senescence under these conditions (Campisi and d’Adda di Fa-
gagna, 2007; Collado et al., 2007). Thus, it has been postulated
that the relative contribution of the p16INK4A and p53 pathways
to senescence might depend on the cellular context and the
type of stress signals (Campisi and d’Adda di Fagagna, 2007).
Our present findings implicate selectively p16INK4A in a heretofore
unreported senescence response invoked in vivo by inflamma-
tory stress in the absence of oncogene activation. The precise
nature of the signals elicited by the inflammatory milieu to
promote the p16INK4A-dependent induction of PDECsenescence
remains to be established. However, experimental acute pancre-
atitis triggered by cerulein administration has been shown to
induce an increase in the levels of proinflammatory cytokines
such as TNF-a, IL-6, IL-8, and IL-10 (Fu et al., 1997; Norman,
1998; Van Laethem et al., 1998). IL-6 and IL-8 have both been
implicated in the senescence response to oncogenic stress
(Acosta et al., 2008; Kuilman et al., 2008), thus raising the possi-
bility that they could play a similar role in the setting of pancreatic
inflammation.
The in vivo and in vitro abrogation of senescence by oncogenic
KRas reported here represents a departure from the more
frequently described senescence-triggering effect of oncogenic
Ras. The latter has been linked predominantly to hyperprolifera-
tive signals that result from a high Ras gene dosage (DeNicola
andTuveson, 2009; Ji et al., 2009;Sarkisian et al., 2007).Our find-
ings demonstrate that PDEC harboring an endogenous allele of
oncogenic KRas not only fail to activate the senescence program
but are wired to suppress senescence through the upregulation
of Twist. This observation is consistent with an earlier finding
that Twist suppresses the senescence of immortalized human
prostate cell lines (Kwok et al., 2007). Moreover, a connection
between Twist expression and senescence bypass has been
documented recently in the setting of oncogenic stress and has
been attributed to the activity of Twist as a transcriptional
repressor of the two senescence inducers p16INK4A and p21CIP
(Ansieau et al., 2008). PDEC expressing oncogenic KRas rely
on the same mechanism, namely Twist-dependent transcrip-
tional repression of p16INK4A, to override premature senescence
caused by environmental stress. As such, the coincident expres-
sion of oncogenic KRas and Twist in PDEC may facilitate the
initiation of the tumorigenic state through the inactivation of
a proliferative barrier imposed by p16INK4A expression. The
increased expression of Twist displayed by human pancreatic
cancer cells lends further support to this idea (Satoh et al.,
2008). It is noteworthy that in studies utilizing mouse models
that are different from the one employed in this study, the
endogenous expression of oncogenic KRas in the pancreas
has been reported to trigger senescence in preneoplastic lesions
(Collado et al., 2005; Morton et al., 2010). The factors that might
contribute to this apparent discrepancy remain to be delineated
but could in principle include both cell autonomous and noncell
autonomous determinants related to strain-dependent variations
in the expression levels of oncogenic KRas, the types of KRas
activating mutation, and the Cre-driving promoters.CanThe loss of p16INK4A function occurs in 90% of pancreatic
cancers and is brought about by mutation, deletion and
epigenetic silencing. However, the inactivation of p16INK4A is
generally seen at a later stage of neoplastic progression subse-
quent to the acquisition of oncogenic KRas mutations (Moskaluk
et al., 1997; Wilentz et al., 1998). Therefore, the expression of
Twist may allow oncogenic KRas-expressing PDEC to escape
senescence at an earlier stage when the p16INK4A locus has not
been disrupted yet. The pressure to lose p16INK4A function as
the disease advances might reflect alterations in Twist transcrip-
tional repressive activity possibly resulting from changes in the
abundance and/or post-translational modifications of Twist
binding partners. The finding that the oncogenic KRas-Twist
axis is exploited in thecontext of inflammation-associated senes-
cence is of particular interest given the compelling evidence both
from human studies and experimental models for a strong link
between pancreatitis and an increased risk of pancreatic cancer
(Carriere et al., 2009; Gidekel Friedlander et al., 2009; Guerra
et al., 2007; Lowenfels et al., 1993; Malka et al., 2002; Morris
et al., 2010). Accordingly, Twist expression could critically affect
the impact of inflammatory conditions on the tumorigenic poten-
tial of pancreatic ductal cells harboring oncogenic KRas.
The induction of Twist by Ras is not unprecedented (Liu et al.,
2009) and studies in Drosophila have reported genetic interac-
tions between Twist and Ras (Hurlbut et al., 2009). However,
the precise signaling events by which Ras stimulates Twist
expression have not been defined. Indeed, it appears that
multiple Ras effector pathways can contribute to an increase in
Twist transcripts. These include the PI3K and ERK pathways
as well as the NF-kB, JAK/STAT, and GSK-3b/b-catenin path-
ways (Dupont et al., 2001; Hong et al., 2009; Howe et al., 2003;
Pham et al., 2007; Sosic et al., 2003; Zhu and Tan, 2005). The
relative engagement of these pathways would vary depending
on cell type and environmental conditions. Thus, the contribution
of the Ras-Twist-p16INK4A axis to senescence bypass is likely to
be context-dependent. Furthermore, although Twist has been
implicated in the induction of EMT programs in epithelial cells
(Yang et al., 2004), our findings indicate this aspect of Twist func-
tion is not essential for its senescence suppressing activity.
In addition to being locked in a state of permanent growth
arrest, senescent cells have been noted to secrete an increased
amount of pro-inflammatory mediators including cytokines, che-
mokines, growth factors, and extracellular proteases (Coppe
et al., 2010; Kuilman and Peeper, 2009). Hence the induction
of ductal cell senescence under conditions of pancreatic injury
and inflammation may constitute a mechanism to maintain and
amplify the inflammatory microenvironment. Given the pro-
tumorigenic impact of inflammatory conditions, senescent
lesions within the pancreas may play a direct role in fueling the
neoplastic process by promoting the unscheduled growth of
precursor cells harboring KRas mutations.
EXPERIMENTAL PROCEDURES
Mice and Cerulein Treatment
The LSL-KrasG12D, p16Ink4a/, p53/, and, p48-Cre strains have been previ-
ously described (Jacks et al., 1994; Jackson et al., 2001; Kawaguchi et al.,
2002; Sharpless et al., 2001). One-month-old mice were subjected to eight
hourly intraperitoneal injections of cerulein (50 ng/g of body weight/injection)
on 2 consecutive days. Pancreata were harvested 3 days after the lastcer Cell 18, 448–458, November 16, 2010 ª2010 Elsevier Inc. 455
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guidelines and were approved by the Institutional Animal Care and Use
Committee at NYU School of Medicine.
Isolation, Culture, and Infection of PDEC
Isolation and culture of PDEC were carried out as previously described (Agbu-
nag et al., 2006). PDEC were isolated from 2–3-month-old mice and propa-
gated in Matrigel (Becton Dickinson). GFP pAdEasy-1 and Cre pAdEasy-1
adenoviral vectors were gifts from Gustavo Leone. Purified adenovirus parti-
cles were obtained by CsCl equilibrium centrifugation. Six hundred adenovirus
particles/cell were added to the PDEC suspension. In a microfuge tube, cell/
virus mixtures were rocked every 15 min for 1 hr at 37C, and then embedded
in Matrigel. Two days later, the infection was repeated. PDEC were propa-
gated in Matrigel, and then transferred to 1% Matrigel-coated plated at the
time of the experiment. Lentiviral vectors containing shRNAs directed against
the Twist gene (shRNA Twist3 and shRNA Twist5) and control shRNA directed
against the Gfp gene were kind gifts from the Robert A. Weinberg laboratory
(Yang et al., 2004). KrasG12D PDEC or p16Ink4a/ PDEC were infected with
lentivirus (multiplicity of infection = 20) using 10 mg/ml polybrene (Chemicon),
cultivated on Matrigel with medium containing 2% Matrigel for 3 days, and
transferred to a 1% Matrigel-coated plate.
KrasG12D Allele Recombination Assay
For verification of Cre-mediated recombination, DNA was prepared from
LSL-KrasG12D PDEC infected with adenoviral-GFP (WT) or adenoviral-Cre
(KrasG12D), or from pancreatic ducts or pancreata from 1-month-old WT or
p48-Cre;LSL-KrasG12D mice by using DNeasy Blood and Tissue kit (QIAGEN).
Genomic DNA was amplified by PCR to demonstrate 265 bp and 305 bp prod-
ucts that are specific for theWT and recombined alleles, respectively (Jackson
et al., 2001).
Ras Activation Assay
The levels of Ras-GTP were determined by the GST–RBD pull-down assay, as
described previously (Boykevisch et al., 2006). The following antibodies were
used: mouse anti-KRas (Santa-Cruz) and mouse anti-a-Tubulin (Sigma).
Senescence-Associated-b-Galactosidase Assay
Adherent cells or frozen sections of pancreatic tissue were fixed with 2% form-
aldehyde/0.2% glutaraldehyde in phosphate buffer solution (PBS) for 3–5 min,
washed with PBS, stained at 37C for 12–16 hr in X-Gal solution (1 mg/ml
X-Gal, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, and
1 mM MgCl2 in PBS at pH6.0), and counterstained with Hoechst 33342
(Invitrogen) for b-gal quantification. Slides were examined on a Zeiss Axiovert
200Mmicroscope. For quantification of SA-b-gal staining in PDEC cultures, at
least 150 cells/fields of viewwere counted. In the pancreatic tissue, pancreatic
ducts bearing 10% or more b-gal-positive cells in each duct were scored as
positive.
Immunoblot Analysis
Cells were lysed with 25mM Tris at pH7.5, 120 mMNaCl, 10 mMMgCl2, 1 mM
EDTA, 1%NP-40, 10% glycerol, 10 mg/ml aprotinin, 1 mM phenylmethanesul-
fonyl fluoride (PMSF), 1 mM Na2VO4, 0.25% sodium deoxycholate, 10 mM
NaF, 10 mg/ml pepstatin, 10 mg/ml leupeptin, 10 mg/ml trypsin inhibitor, and
10mMbenzamidine. Cell lysates were separated by electrophoresis in sodium
dodecyl sulfate (SDS) polyacrylamide gels and transferred to nitrocellulose
membranes. After blocking, the membranes were incubated with primary anti-
bodies. Subsequently, membranes were incubated with IRDye 800-conju-
gated goat anti-rabbit (Rockland) or Alexa Fluor 680 goat anti-mouse (Molec-
ular Probes) and visualized with the Odyssey Infrared Imaging System (Li-Cor).
The following antibodies were used: rabbit anti-p16INK4A (Santa-Cruz), rabbit
anti-p19ARF (gift from Charles J. Sherr), mouse anti-p21CIP (Becton Dickinson),
mouse anti-p53 (Santa-Cruz), rabbit anti-Twist (Santa-Cruz), and mouse anti-
a-Tubulin (Sigma).
Quantitative RT-PCR
Total RNA was extracted from PDEC or pancreata by using RNeasy mini kit
(QIAGEN) and reverse transcribed with QuantiTect reverse transcription kit456 Cancer Cell 18, 448–458, November 16, 2010 ª2010 Elsevier Inc(QIAGEN). PCR reactions were performed using the SYBR Green PCR Master
Mix (USB). Expression levels were normalized by cyclophilin A.
Human Pancreas Specimens
The use of human tissue for this study was reviewed and approved by the Insti-
tutional Review Board of NYU School of Medicine and samples were obtained
after informed consent. Sections (5 mm) were cut from formalin-fixed paraffin-
embedded samples for the purpose of immunohistochemistry.
Histology and Immunofluorescence
Pancreata were removed and snap frozen in OCT compound (Tissue-Tek).
Sections of 8 mm were air-dried and hydrated in 70% ethanol. Hematoxylin
and eosin (H&E) staining was performed by incubation in hematoxylin (Sigma)
followed by eosin (Sigma). Sections were dehydrated (70%, 95%, 100%
ethanol) and mounted with Permount (Fisher). For immunofluorescence of
pancreata, frozen sections were fixed in 4%paraformaldehyde for 10min, per-
meabilized with 0.25% Triton X-100 for 10 min, and blocked with 10% serum/
0.1% Tween-20 for 1 hr. Slides were incubated with primary antibodies diluted
in 1% BSA/0.5% Tween-20 overnight at 4C. Slides were then incubated with
Alexa Fluor-labeled secondary antibodies (Invitrogen) diluted in 1% BSA for
1 hr and mounted using Vectashield mounting medium with DAPI (Vector
Laboratories). For immunofluorescence of PDEC, cells grown on 1% Matri-
gel-coated coverslips were fixed in 3% paraformaldehyde for 30 min, permea-
bilized with 0.2% Triton X-100 for 10 min, and blocked with 2% BSA for 1 hr.
PDEC were incubated with primary antibodies diluted in 2% BSA for 1 hr
followed by Alexa Fluor-labeled secondary antibodies (Invitrogen) diluted in
2%BSA for 1 hr. PDECwere then incubated with DAPI for 15min andmounted
with Immuno-mount (Shandon) containing 0.04% paranitrodiphenylene
(Sigma). Slides were examined on a Zeiss Axiovert 200M microscope. The
following antibodies were used: rat anti-CD45 (Becton Dickinson), rat
anti-CK19 (TromaIII, developed by Rolf Kemler and obtained from Develop-
mental Studies Hybridoma Bank), mouse anti-E-cadherin (Becton Dickinson),
rabbit anti-Ki67 (Novocastra), rabbit anti-p16INK4A (Santa-Cruz), and mouse
anti-a-SMA (Sigma).
Immunohistochemistry
Pancreata were fixed in 10% formalin overnight and embedded in paraffin. For
immunohistochemistry, slides (5 mm) were deparaffinized, rehydrated,
quenched in 0.6% hydrogen peroxide/methanol for 15 min, and antigens
were boiled for 15 min in a microwave oven in 10 mM sodium citrate (pH 6.0)
for antigen retrieval. Sections were blocked with 5% serum/1% BSA/0.5%
Tween-20 for 1 hr. Slides were incubated with primary antibodies diluted in
blocking buffer overnight at room temperature. Following the primary antibody,
slides were incubated with biotinylated secondary antibodies (Vector Labora-
tories) followed by ABC solution (Vector Laboratories) and developed with
3,30-diaminobenzidine tetrahydrochloride for 15 min. Slides were counter-
stained with hematoxylin, dehydrated, and mounted with Permount (Fisher).
Slides were examined on a Zeiss Axiovert 200M microscope. The following
antibodies were used: mouse anti-p16INK4A (Santa-Cruz) and rat anti-CD45
(Becton Dickinson).
Statistical Analyses
Data were analyzed by Student’s t test (paired, two-tailed) and results were
considered significant at p value < 0.05. Results are presented as mean and
standard deviation.
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